Drug Profile


Alternative Names: Allogeneic stem cell therapy - ViaCyte; Encapsulated human islet cell therapy - ViaCyte; Encapsulated islet cell transplantation therapy - ViaCyte; Encapsulated pancreatic cell therapy - ViaCyte; Encapsulated pancreatic cell transplantation therapy - ViaCyte; Pancreatic beta cell replacement therapy - ViaCyte; PEC-EnCap; PEC-Encap™; Pro-Islet; VC-01

Latest Information Update: 29 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Type-2 diabetes mellitus in USA (SC) before April 2017
  • 29 Mar 2017 ViaCyte and W. L. Gore & Associates collaborate to develop novel implantable delivery technologies for cell therapies
  • 01 Oct 2016 ViaCyte initiates an observational, follow-up clinical trial for Type-1 diabetes mellitus in USA and Canada (NCT02939118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top